Compare Mesoblast Limited (MESO) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Oatly Group AB - ADR — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Oatly Group AB - ADR trades at $10.59 (market cap $330.93M). The key difference: Mesoblast Limited is far larger — about 5.3× Oatly Group AB - ADR's market cap, and Oatly Group AB - ADR is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Oatly Group AB - ADR for 18 Days on average.
| MESO | OTLY | |
|---|---|---|
Market Cap | $1.75B | $330.93M |
Volume | 239,027 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $20.96 | $15.91 |
52-Week Low | $13.19 | $8.03 |
Typical Hold Time | 15 Days | 18 Days |
Enterprise Value | $1.83B | $835.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
OTLY trades at $10.38, up 0.1% on the day, with a bearish technical signal but improving fundamentals. Revenue grew to $862.46M in 2025, and net losses narrowed to -$152.77M, showing progress toward profitability. The stock is supported by a consensus price target of $12.28 and positive news around Q2 2026 results, including a raised revenue outlook.
The outlook is cautiously optimistic as cost controls and sales growth may lead to positive EBITDA, but high debt and persistent cash burn pose risks. Analyst sentiment is mixed with 44% buy ratings, reflecting belief in the turnaround story amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
